Conatus Late-breaker Oral Presentation at EASL Meeting to Detail Results of ENCORE-PH Phase 2b Clinical Trial in Patients wit...
March 13 2019 - 9:00AM
Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) announced today the
acceptance of an abstract for a late-breaker oral presentation at
The International Liver Congress™ 2019, the Annual Meeting of the
European Association for the Study of the Liver (EASL) in Vienna,
Austria, April 10-14.
The oral presentation at EASL entitled,
“Multicenter, Double-blind, Placebo-controlled, Randomized Trial of
Emricasan in Subjects with NASH Cirrhosis and Severe Portal
Hypertension (PH),” (#LB01) will detail results from the company’s
Phase 2b ENCORE-PH clinical trial of emricasan, the company’s
first-in-class, orally active pan-caspase protease inhibitor.
Guadalupe Garcia-Tsao, M.D., Professor of Medicine in the Section
of Digestive Diseases at Yale School of Medicine, Director of the
Clinical and Translational Core at Yale Liver Center, Chief of the
Section of Digestive Diseases at the Veterans
Administration-Connecticut Health Care System, and the central
reader in the ENCORE-PH trial, will deliver the presentation on
Saturday, April 13, at 4:00 p.m. CEST.
About Conatus
PharmaceuticalsConatus is a biotechnology company focused
on the development and commercialization of novel medicines to
treat chronic diseases with significant unmet need. In
collaboration with Novartis, Conatus is developing its lead
in-licensed compound, emricasan, for the treatment of patients with
NASH-driven chronic liver diseases. Conatus is independently
developing its lead internally developed compound, CTS-2090, for
the treatment of patients with chronic diseases involving
inflammasome pathways. For additional information, please visit
www.conatuspharma.com.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended. All statements other than statements of historical facts
contained in this press release are forward looking
statements. In some cases, you can identify forward-looking
statements by terms such as “may,” “will,” “should,” “expect,”
“plan,” “anticipate,” “could,” “intend,” “target,” “project,”
“contemplates,” “believes,” “estimates,” “predicts,” “potential” or
“continue” or the negative of these terms or other similar
expressions. These forward-looking statements speak only as of
the date of this press release and are subject to a number of
risks, uncertainties and assumptions, including those risks
described in the company’s prior press releases and in the periodic
reports it files with the Securities and Exchange
Commission. The events and circumstances reflected in the
company’s forward-looking statements may not be achieved or occur
and actual results could differ materially from those projected in
the forward-looking statements. Except as required by applicable
law, the company does not plan to publicly update or revise any
forward-looking statements contained herein, whether as a result of
any new information, future events, changed circumstances or
otherwise.
Conatus Pharmaceuticals (NASDAQ:CNAT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Conatus Pharmaceuticals (NASDAQ:CNAT)
Historical Stock Chart
From Apr 2023 to Apr 2024